Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017
EyeCRO and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and experience of both organizations, including the highly specialized ophthalmology capabilities at MPI Research and the expertise in new model development at EyeCRO.
“There is a dire need to develop large animal preclinical models of ophthalmic disease that permit clinically translatable routes of administration and reliable examination of test agent activity,” said Rafal Farjo, Ph.D., Chief Executive Officer of EyeCRO. “The scientific staff, capabilities, and extensive track record of success at MPI Research will allow for rapid development and commercialization of these important models. This collaboration will allow drug developers to fully understand the therapeutic potential of their programs so they can accelerate advancement of these important sight-saving treatments into the clinic.”
“The team at EyeCRO is widely recognized as a global leader in preclinical ophthalmic research,” said Josh Bartoe, DVM, DACVO, Director of Ophthalmology Services at MPI Research. “Their extensive experience in developing and advancing translatable models and endpoints in preclinical ophthalmic studies will be a tremendous asset in this endeavor. We look forward to incorporating the scientific aptitude of the EyeCRO team into our existing ophthalmology division as we develop meaningful preclinical models to assist the drug development community.”
EyeCRO also announced the official opening of a new research and development site laboratory in Ann Arbor, Michigan. This location includes 3,500 sq.ft. of wet-research laboratory space and EyeCRO will seek full AAALAC accreditation for preclinical research performed here. “This second EyeCRO laboratory will focus on new model development and implementation of translational research studies with several clinician-scientists in the area. The new laboratory is also conveniently located within 90 minutes of the MPI headquarters, which will allow greater lines of communication and collaboration to advance the partnership between our scientists,” said Dr. Farjo.
According to the National Eye Institute, there are more than 36 million adults over the age of 40 with vision impairment and age-related diseases of the eye in the United States. Current projections expect the prevalence for certain diseases, such as Age-Related Macular Degeneration and Diabetic Retinopathy, to nearly double by 2030; thus, there is a strong clinical need to advance vision-saving treatments that can ameliorate ophthalmic disease through multiple mechanisms of action.
EyeCRO is a global leader in the performance of preclinical ophthalmic research to advance therapeutic discovery and development programs. The company has laboratories in Oklahoma City, OK and Ann Arbor, MI which provides a number of validated contract research services to the ophthalmic research community worldwide. The company conducts preclinical studies in a number of well-established models to accurately evaluate the activity, safety, and pharmacokinetics of test agents for treating diseases such as Age-Related Macular Degeneration, Diabetic Retinopathy, Dry Eye, Allergic Conjunctivitis, Retinitis Pigmentosa, Leber's Congenital Amaurosis, Glaucoma, and Uveitis. In addition, the patented MiDROPS™ platform allows for formulation and eyedrop delivery of lipophilic small molecules to both the front and back of the eye. For more information, visit http://www.EyeCRO.com
About MPI Research
MPI Research is a leading early stage drug and device development CRO providing discovery and preclinical services to the biopharmaceutical, medical device, animal health, and chemical industries. MPI Research works to advance global healthcare by bringing the best in contracted scientific research alongside the missions of Sponsors throughout the world. The company is grounded in a commitment to exceptional service, best-in-class quality and a consultative approach. The MPI Research team consists of highly experienced Study Directors, specialized scientists, and industry leaders with the breadth and depth of experience necessary to support Sponsor needs. Find out more at http://www.mpiresearch.com